Elevated urine BMP phospholipids in LRRK2 and VPS35 mutation carriers with and without Parkinson's disease
-
Gomes, Sara1
- Garrido, Alicia2
- Tonelli, Francesca1
- Obiang, Donina2
- Tolosa, Eduardo2
- Marti, Maria Jose3
- Ruiz-Martinez, Javier4
- Vinagre Aragon, Ana5
- Hernandez-Eguiazu, Haizea6
- Croitoru, Ioana5
- L Marshall, Vicky7
- Koenig, Theresa8
- Hotzy, Christoph8
- Hsieh, Frank9
- Sakalosh, Marianna9
- Tengstrand, Elizabeth9
- Padmanabhan, Shalini10
- Merchant, Kalpana10
- Bruecke, Christof8
- Pirker, Walter11
- Zimprich, Alexander8
- Sammler, Esther12
- 1. Medical Research Council Protein Phosphorylation and Ubiquitylation Unit, University of Dundee, Dundee DD1 5EH, UK
- 2. Parkinson's Disease and Movement Disorders Unit, Institut Clínic de Neurociències, Hospital Clinic Universitari, Barcelona, Spain. Centre for Networked Biomedical Research on Neurodegenerative Diseases (CIBERNED), Madrid, Spain
- 3. Parkinson's Disease and Movement Disorders Unit, Institut Clínic de Neurociències, Hospital Clinic Universitari, Barcelona, Spain. Centre for Networked Biomedical Research on Neurodegenerative Diseases (CIBERNED), Madrid, Spain Department of Clinical and Experimental Neurology, Laboratory of Parkinson disease and other Neurodegenerative Movement Disorders (IDIBAPS), University of Barcelona, Barcelona, Spain
- 4. Centre for Networked Biomedical Research on Neurodegenerative Diseases (CIBERNED), Madrid, Spain Hospital Universitario Donostia, San Sebastián, Spain Group of Neurodegenerative Diseases, Biodonostia Research Institute, San Sebastián, Spain
- 5. Hospital Universitario Donostia, San Sebastián, Spain Group of Neurodegenerative Diseases, Biodonostia Research Institute, San Sebastián, Spain
- 6. Group of Neurodegenerative Diseases, Biodonostia Research Institute, San Sebastián, Spain
- 7. Neurology, Queen Elizabeth University Hospital, Institute of Neurological Sciences, Glasgow, UK
- 8. Department of Neurology, Medical University of Vienna, Wien, Austria
- 9. Nextcea, Inc. 500 West Cummings Park, Suite 4550, Woburn, Massachusetts, USA
- 10. The Michael J. Fox Foundation for Parkinson's Research, New York, NY, USA
- 11. Department of Neurology, Klinik Ottakring, Vienna, Austria
- 12. Medical Research Council Protein Phosphorylation and Ubiquitylation Unit, University of Dundee, Dundee DD1 5EH, UK Molecular and Clinical Medicine, Ninewells Hospital and Medical School, University of Dundee, UK
Description
Participant demographic and clinical characteristics, and urine BMP phospholipid levels.
For each participant, sample collection site is provided as: BCN (Barcelona), VIE (Vienna), DND (Dundee), or SSB (San Sebastian). Also provided are age at study participation, age at PD diagnosis (where applicable), sex (M, for male, and F, for female), experimental group (control, iPD –idiopathic PD –, LRRK2 G2019S, LRRK2 R1441G/C, VPS35 D620N, GBA, or other), and PD status (NMC for non-manifesting mutation carriers, or PD). Values for all measured BMP species presented as ng of BMP per mg of creatinine are provided. Additionally, urine creatinine (mg/ml) and non-normalized BMP levels are provided. BQL designates BMP levels that were below quantification level and NM designates values that were not measured for a particular individual.
Files
R_report.pdf
Additional details
Related works
- Is published in
- Journal article: 10.1038/s41531-023-00482-4 (DOI)